Astaxanthin: A Novel Potential Treatment for Oxidative Stress and Inflammation in Cardiovascular Disease

American Journal of Cardiology

Volumn 101, Issue 10 SUPPL., 2008, Pages

  Pashkow, Fredric J ^a,b   Watumull, David G ^b   Campbell, Charles L ^c  

^a UNIVERSITY OF HAWAII   (United States)

^b Cardax Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASTAXANTHIN; ASTAXANTHIN DISUCCINATE DISODIUM SALT; BETA CAROTENE; FREE RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; XANTHOPHYLL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY THROMBOSIS; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; XANTHOPHYLLS;

EID: 43049167532     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.010     Document Type: Article

References (51)

1. Fuster V., Moreno P.R., Fayad Z.A., Corti R., and Badimon J.J. Atherothrombosis and high-risk plaque. Part I: evolving concepts. J Am Coll Cardiol 46 (2005) 937-954
2. Tedgui A., and Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86 (2006) 515-581
3. Geisler T., and Bhatt D.L. The role of inflammation in atherothrombosis: current and future strategies of medical treatment. Med Sci Monit 10 (2004) RA308-RA316
4. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39 (2007) 44-84
5. Davidson S.M., and Duchen M.R. Endothelial mitochondria: contributing to vascular function and disease. Circ Res 100 (2007) 1128-1141
6. Muller G., Goettsch C., and Morawietz H. Oxidative stress and endothelial dysfunction. Hamostaseologie 27 (2007) 5-12
7. Schulz E., Anter E., and Keaney Jr. J.F. Oxidative stress, antioxidants, and endothelial function. Curr Med Chem 11 (2004) 1093-1104
8. Tak P.P., and Firestein G.S. NF-κB: a key role in inflammatory diseases. J Clin Invest 107 (2001) 7-11
9. Li Q., and Verma I.M. NF-κB regulation in the immune system. Nat Rev Immunol 2 (2002) 725-734
10. Cyrus T., Sung S., Zhao L., Funk C.D., Tang S., and Pratico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 106 (2002) 1282-1287
11. Cominacini L., Anselmi M., Garbin U., Fratta Pasini A., Stranieri C., Fusaro M., Nava C., Agostoni P., Keta D., Zardini P., Sawamura T., and Lo Cascio V. Enhanced plasma levels of oxidized low-density lipoprotein increase circulating nuclear factor-κB activation in patients with unstable angina. J Am Coll Cardiol 46 (2005) 799-806
12. Bertram J.S. Cellular communication via gap junctions. Sci Med (Phila) 8 (2000) 18-27
13. Chadjichristos C.E., Derouette J.P., and Kwak B.R. Connexins in atherosclerosis. Adv Cardiol 42 (2006) 255-267
14. Dhein S. Cardiac ischemia and uncoupling: gap junctions in ischemia and infarction. Adv Cardiol 42 (2006) 198-212
15. Severs N.J., Dupont E., Thomas N., Kaba R., Rothery S., Jain R., Sharpey K., and Fry C.H. Alterations in cardiac connexin expression in cardiomyopathies. Adv Cardiol 42 (2006) 228-242
16. Murray K.T., Mace L.C., and Yang Z. Nonantiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm 4 (2007) S88-S90
17. Dhein S. Role of connexins in atrial fibrillation. Adv Cardiol 42 (2006) 161-174
18. Rodriguez-Sinovas A., Boengler K., Cabestrero A., Gres P., Morente M., Ruiz-Meana M., Konietzka I., Miro E., Totzeck A., Heusch G., Schulz R., and Garcia-Dorado D. Translocation of connexin 43 to the inner mitochondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM pathway and its importance for cardioprotection. Circ Res 99 (2006) 93-101
19. Boengler K., Konietzka I., Buechert A., Heinen Y., Garcia-Dorado D., Heusch G., and Schulz R. Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. Am J Physiol Heart Circ Physiol 292 (2007) H1764-H1769
20. Hix L.M., Lockwood S.F., and Bertram J.S. Upregulation of connexin 43 protein expression and increased gap junctional communication by water soluble disodium disuccinate astaxanthin derivatives. Cancer Lett 211 (2004) 25-37
21. Rodrigo R., Guichard C., and Charles R. Clinical pharmacology and therapeutic use of antioxidant vitamins. Fundam Clin Pharmacol 21 (2007) 111-127
22. McNulty H.P., Byun J., Lockwood S.F., Jacob R.F., and Mason R.P. Differential effects of carotenoids on lipid peroxidation due to membrane interactions: X-ray diffraction analysis. Biochim Biophys Acta 1768 (2007) 167-174
23. May J.M. Is ascorbic acid an antioxidant for the plasma membrane?. FASEB J 13 (1999) 995-1006
24. Hussein G., Sankawa U., Goto H., Matsumoto K., and Watanabe H. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod 69 (2006) 443-449
25. Santocono M., Zurria M., Berrettini M., Fedeli D., and Falcioni G. Influence of astaxanthin, zeaxanthin and lutein on DNA damage and repair in UVA-irradiated cells. J Photochem Photobiol B 85 (2006) 205-215
26. Lockwood S.F., and Gross G.J. Disodium disuccinate astaxanthin (Cardax): antioxidant and antiinflammatory cardioprotection. Cardiovasc Drug Rev 23 (2005) 199-216
27. Guerin M., Huntley M.E., and Olaizola M. Haematococcus astaxanthin: applications for human health and nutrition. Trends Biotechnol 21 (2003) 210-216
28. Wang X.D., Krinsky N.I., Marini R.P., Tang G., Yu J., Hurley R., Fox J.G., and Russell R.M. Intestinal uptake and lymphatic absorption of beta-carotene in ferrets: a model for human beta-carotene metabolism. Am J Physiol 263 (1992) G480-G486
29. Astaxanthin as a pigmenter in salmon feed. Chemicals HVF (1987) Hoffman-La Roche Inc.
30. Spiller G.A., and Dewell A. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. J Med Food 6 (2003) 51-56
31. Félétou M., and Vanhoutte P.M. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 291 (2006) H985-H1002
32. Nicholls S.J., Zheng L., and Hazen S.L. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 15 (2005) 212-219
33. Levitsky S. Protecting the myocardial cell during coronary revascularization: the William WL Glenn Lecture. Circulation 114 (2006) I339-I343
34. Van Wagoner D.R. Recent insights into the pathophysiology of atrial fibrillation. Semin Thorac Cardiovasc Surg 19 (2007) 9-15
35. Dzau V.J., Antman E.M., Black H.R., Hayes D.L., Manson J.E., Plutzky J., Popma J.J., and Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. Part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 114 (2006) 2850-2870
36. Iwamoto T., Hosoda K., Hirano R., Kurata H., Matsumoto A., Miki W., Kamiyama M., Itakura H., Yamamoto S., and Kondo K. Inhibition of low-density lipoprotein oxidation by astaxanthin. J Atheroscler Thromb 7 (2000) 216-222
37. Mason R.P., Walter M.F., McNulty H.P., Lockwood S.F., Byun J., Day C.A., and Jacob R.F. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. J Cardiovasc Pharmacol 47 suppl 1 (2006) S7-S14
38. Gross G.J., and Auchampach J.A. Reperfusion injury: does it exist?. J Mol Cell Cardiol 42 (2007) 12-18
39. Wang Q.D., Pernow J., Sjoquist P.O., and Ryden L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res 55 (2002) 25-37
40. Gross G.J., and Lockwood S.F. Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts. Mol Cell Biochem 272 (2005) 221-227
41. Gross G.J., and Lockwood S.F. Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax). Life Sci 75 (2004) 215-224
42. Gross G.J., Hazen S.L., and Lockwood S.F. Seven day oral supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats. Mol Cell Biochem 283 (2006) 23-30
43. Krotz F., Sohn H.Y., and Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 24 (2004) 1988-1996
44. Lauver DA, Driscoll EM, Lucchesi BR. Disodium disuccinate astaxanthin prevents carotid rethrombosis and ex-vivo platelet activation. Pharmacology (in press).
45. Hall G., Hasday J.D., and Rogers T.B. Regulating the regulator: NF-κB signaling in heart. J Mol Cell Cardiol 41 (2006) 580-591
46. Higuchi Y., Otsu K., Nishida K., Hirotani S., Nakayama H., Yamaguchi O., Matsumura Y., Ueno H., Tada M., and Hori M. Involvement of reactive oxygen species-mediated NF-κB activation in TNF-α-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 34 (2002) 233-240
47. Molkentin J.D., and Dorn II I.G. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63 (2001) 391-426
48. Matsumori A., and Sasayama S. The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure. Heart Fail Rev 6 (2001) 129-136
49. Cook S.A., Novikov M.S., Ahn Y., Matsui T., and Rosenzweig A. A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation 108 (2003) 664-667
50. Lee S.J., Bai S.K., Lee K.S., Namkoong S., Na H.J., Ha K.S., Han J.A., Yim S.V., Chang K., Kwon Y.G., Lee S.K., and Kim Y.M. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(κ)B kinase-dependent NF-κB activation. Mol Cells 16 (2003) 97-105
51. Ohgami K., Shiratori K., Kotake S., Nishida T., Mizuki N., Yazawa K., and Ohno S. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci 44 (2003) 2694-2701